CureVac’s stock is up 8% as it shares additional Phase 1 data about its COVID-19 vaccine candidate

/ / News

Shares of CureVac gained 8.0% in premarket trading on Tuesday after the company disclosed additional clinical data about how its COVID-19 vaccine candidate is performing in a Phase 1 clinical trial. Interim data from an early-stage clinical trial was published Tuesday as a preprint, according to the U.S.-listed German company, which is running clinical trials for its experimental RNA vaccine in Belgium and Germany. (CureVac has previously disclosed some clinical data from the trial in a news release on Nov. 2.) It said it also expects to publish the data in a peer-reviewed medical journal, which is considered the gold standard of disseminating medical information. CureVac’s Phase 1 study tested different doses of the two-dose vaccine in adults between the ages of 18 and 60 years old; all doses generated an immune response. The company said it has selected the 12 microgram dose to move forward with in Phase 2 and 3 studies, which plan to enroll more than 36,000 people. CureVac’s stock has soared 781.6% so far this year. The S&P 500 is up 9.9% year-to-date.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.